Poland· PL-100538061
Rhapsido
A selective immunosuppressants product containing remibrutinib, registered in Poland by Novartis Europharm Limited. The same ATC class is registered in 5 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Remibrutinib is registered in 5 of 19 countries.
Countries holding a registration under ATC L04AA (selective immunosuppressants), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 2 of them publish a price we can compare per daily dose
Remibrutinib · ATC L04AA
5 / 19 countries
- Denmark
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Remibrutinib
- Manufacturer
- Novartis Europharm Limited
- Country
- Poland (PL)
- ATC code
- L04AA
- ATC class
- Selective immunosuppressants
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin07613421253219
- gtin07613421252083
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Remibrutinib in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRHAPSIDONovartis Europharm Limited, Dublin
- SpainRHAPSIDO 25 MG COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- FinlandRhapsidoNovartis Europharm Limited
- IrelandRhapsido 25 mg film-coated tabletsNovartis Europharm Limited
- IcelandRhapsidoNovartis Europharm Limited*
- NetherlandsRhapsido 25 mg filmomhulde tablettenNovartis Europharm Limited
- BelgiumRhapsido 25 mgNovartis Europharm
- SwedenRhapsido 25 mg Filmdragerad tablettNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rhapsido
- Liechtenstein · Rhapsido
- Norway · Rhapsido
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/40e806ba-01c3-4d4a-a8cc-2ba7fe34b4c9 GET /v1/drugs/40e806ba-01c3-4d4a-a8cc-2ba7fe34b4c9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "25 mg",
"packaging": "07613421253219 ¦ Rpz ¦ EU/1/26/2024/001 ¦ 167014\n30 tabl.\n07613421252083 ¦ Rpz ¦ EU/1/26/2024/002 ¦ 167015\n60 tabl.\nRpz ¦ EU/1/26/2024/003 ¦ 167016\n180 tabl.",
"substance": "Remibrutinib 25 mg",
"common_name": "Remibrutinib",
"pl_product_id": "100538061",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about remibrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.